Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S266-KLH is an immunoconjugate consisting of the synthetic small-molecule hapten S266 covalently conjugated to keyhole limpet hemocyanin (KLH), a large, highly immunogenic carrier protein derived from the sea mollusk *Megathura crenulata*. The S266-KLH conjugate is designed to elicit a strong immune response specifically against the S266 hapten, making it useful for generation of anti-S266 antibodies in research, preclinical, or clinical settings. KLH itself acts as a powerful immunostimulant, provoking both humoral and cellular immunity through mechanisms involving various immune cells such as T cells, monocytes, macrophages, and dendritic cells. This type of immunoconjugate has utility as a vaccine platform, immune system challenge agent, or as an immunogen for antibody production[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S266-KLH.